Roxane Labrosse,Julia Chu,Myriam Armant,John K Everett,Danilo Pellin,Niharika Kareddy,Andrew L Frelinger,Lauren A Henderson,Amy E O'Connell,Amlan Biswas,Jet Coenen-van der Spek,Alexandra Marina Miggelbrink,Claudia Fiorini,Hriju Adhikari,Charles C Berry,Vito Adrian Cantu,Johnson Fong,Jason Roy Jaroslavsky,Derin F Karadeniz,Quan-Zhen Li,Shantan Reddy,Aoife M Roche,Chengsong Zhu,Jennifer S Whangbo,Colleen Dansereau,Brenda L Mackinnon,Emily Morris,Stephanie M Koo,Wendy B London,Safa Baris,Ahmet Ozen,Elif Karakoc-Aydiner,Jenny McDade Despotovic,Lisa R Forbes Satter,Akihiko Saitoh,Yuta Aizawa,Alejandra King,Mai Anh T Nguyen,Vy Do Uyen Vu,Scott B Snapper,Anne Galy,Luigi D Notarangelo,Frederic D Bushman,David A Williams,Sung-Yun Pai,Amy E. O'Connell,Charles C. Berry,Derin F. Karadeniz,Stephanie M. Koo,Mai Anh T. Nguyen,Scott B. Snapper,Frederic D. Bushman

Abstract:Reconstitution of platelets and myeloid function correlated strongly with the number of vector copies in individual transduced stem cells Patients with poor reconstitution of Treg and Breg compartments may be at risk of ongoing autoimmunity despite high-level gene marking Wiskott-Aldrich syndrome (WAS) is a rare X-linked disorder characterized by combined immunodeficiency, eczema, microthrombocytopenia, autoimmunity, and lymphoid malignancies. Gene therapy (GT) to modify autologous CD34+ cells is an emerging alternative treatment with advantages over standard allogeneic hematopoietic stem cell transplant for patients who lack well-matched donors, avoiding graft-versus-host-disease. We report the outcomes of a phase I/II clinical trial in which 5 patients with severe WAS underwent GT using a self-inactivating lentiviral (SIN-LV) vector expressing the human WAS cDNA under the control of a 1.6kB fragment of the autologous promoter after busulfan and fludarabine conditioning. All subjects were alive and well with sustained multi-lineage vector gene marking (median follow-up: 7.6 years). Clinical improvement of eczema, infections and bleeding diathesis was universal. Immune function was consistently improved despite sub-physiological levels of transgenic WAS protein expression. Improvements in platelet count and cytoskeletal function in myeloid cells were most prominent in patients with high vector copy number in the transduced product. Two patients with a history of autoimmunity had flares of autoimmunity post-GT, despite similar percentages of WASp-expressing cells and gene marking as those without autoimmunity. Patients with flares of autoimmunity demonstrated poor numerical recovery of T cells and regulatory T cells (Tregs), IL-10 producing regulatory B cells (Bregs), and transitional B cells. Recovery of the Breg compartment, along with Tregs, thus appears to be protective against development of autoimmunity post-GT. These results indicate that clinical and laboratory manifestations of WAS are improved with GT with an acceptable safety profile. This trial is registered with ClinicalTrials.gov (NCT01410825).

Hematologic Cancer after Gene Therapy for Cerebral Adrenoleukodystrophy

Lentiviral Gene Therapy for Cerebral Adrenoleukodystrophy

Recent Developments in Gene Therapy and Immunotherapy

Hematopoietic stem-cell gene therapy is associated with restored white matter microvascular function in cerebral adrenoleukodystrophy

Hematopoietic stem cell therapy and ex vivo gene therapy for X-linked adrenoleukodystrophy

Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy

Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B

Successes and challenges in clinical gene therapy

A case of T-cell acute lymphoblastic leukemia in retroviral gene therapy for ADA-SCID

Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers: a Beat Childhood Cancer Research Consortium trial

Outcomes of Hematopoietic Stem Cell Gene Therapy for Wiskott-Aldrich Syndrome

Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy

Acute Myeloid Leukemia Case after Gene Therapy for Sickle Cell Disease

Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1

Hematopoietic Stem Cell Gene Therapy: Progress and Lessons Learned

Clonal Hematopoiesis is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma.

International Society for Cell & Gene Therapy Stem Cell Engineering Committee: Cellular therapies for the treatment of graft-versus-host-disease after hematopoietic stem cell transplant

Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors

Long-term and real-world safety and efficacy of retroviral gene therapy for adenosine deaminase deficiency

Clonal Hematopoiesis and Therapy-Related Myeloid Neoplasms After Autologous Transplant for Hodgkin Lymphoma

Hematopoietic Cell Transplantation Cures Adenosine Deaminase 2 Deficiency: Report on 30 Patients